BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 1973178)

  • 1. Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion.
    Ambrosi B; Bochicchio D; Fadin C; Colombo P; Faglia G
    J Endocrinol Invest; 1990 Mar; 13(3):257-61. PubMed ID: 1973178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of atrial natriuretic factor infusion on basal and CRH-stimulated ACTH, cortisol and aldosterone levels in patients with Cushing's or Addison's disease.
    Ambrosi B; Sala C; Bochicchio D; Colombo P; Gazzano G; Fadin C; Morganti A; Faglia G
    Clin Endocrinol (Oxf); 1994 May; 40(5):589-94. PubMed ID: 8013139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of desmopressin on ACTH and cortisol secretion in states of ACTH excess.
    Colombo P; Passini E; Re T; Faglia G; Ambrosi B
    Clin Endocrinol (Oxf); 1997 Jun; 46(6):661-8. PubMed ID: 9274696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pulsatile human corticotropin-releasing hormone administration on the adrenal insufficiency that follows cure of Cushing's disease.
    Avgerinos PC; Nieman LK; Oldfield EH; Loughlin T; Barnes KM; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1989 May; 68(5):912-6. PubMed ID: 2541160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human corticotropin-releasing hormone test in patients with hypothalamo-pituitary-adrenocortical disorders.
    Fukata J; Shimizu N; Imura H; Hibi I; Tanaka K; Tanaka T; Nakagawa S; Takebe K; Kimura K; Yoshinaga K
    Endocr J; 1993 Oct; 40(5):597-606. PubMed ID: 7951526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of repetitive administration of corticotropin-releasing hormone combined with lysine vasopressin on plasma adrenocorticotropin and cortisol levels in secondary adrenocortical insufficiency.
    Fukata J; Usui T; Tsukada T; Nakai Y; Koh T; Ishihara T; Tanaka I; Uchida K; Yoshimasa T; Nakano R
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1624-31. PubMed ID: 2172283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide exerts different effects in vivo and in vitro in Cushing's disease.
    Stalla GK; Brockmeier SJ; Renner U; Newton C; Buchfelder M; Stalla J; Müller OA
    Eur J Endocrinol; 1994 Feb; 130(2):125-31. PubMed ID: 8130885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of the desmopressin test in the postoperative evaluation of patients with Cushing's disease.
    Colombo P; Dall'Asta C; Barbetta L; Re T; Passini E; Faglia G; Ambrosi B
    Eur J Endocrinol; 2000 Aug; 143(2):227-34. PubMed ID: 10913942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of loperamide on the human hypothalamo-pituitary-adrenal axis in vivo and in vitro.
    Auernhammer CJ; Stalla GK; Lange M; Pfeiffer A; Müller OA
    J Clin Endocrinol Metab; 1992 Aug; 75(2):552-7. PubMed ID: 1322429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.
    Ghigo E; Arvat E; Ramunni J; Colao A; Gianotti L; Deghenghi R; Lombardi G; Camanni F
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a role for somatostatin and its analogs in Cushing's syndrome?
    de Herder WW; Lamberts SW
    Metabolism; 1996 Aug; 45(8 Suppl 1):83-5. PubMed ID: 8769391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin treatment reduces the exaggerated response of adrenocorticotropin hormone and cortisol to corticotropin-releasing hormone in polycystic ovary syndrome.
    Lanzone A; Fulghesu AM; Guido M; Cucinelli F; Caruso A; Mancuso S
    Fertil Steril; 1997 Jan; 67(1):34-9. PubMed ID: 8986680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combined test using desmopressin and corticotropin-releasing hormone in the differential diagnosis of Cushing's syndrome.
    Newell-Price J; Perry L; Medbak S; Monson J; Savage M; Besser M; Grossman A
    J Clin Endocrinol Metab; 1997 Jan; 82(1):176-81. PubMed ID: 8989255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of ectopic Cushing's syndrome with the long-acting somatostatin analog octreotide.
    De Rosa G; Testa A; Liberale I; Pirronti T; Granone P; Picciocchi A
    Exp Clin Endocrinol; 1993; 101(5):319-25. PubMed ID: 8299710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GIP-dependent adrenal Cushing's syndrome with incomplete suppression of ACTH.
    Croughs RJ; Zelissen PM; van Vroonhoven TJ; Hofland LJ; N'Diaye N; Lacroix A; de Herder WW
    Clin Endocrinol (Oxf); 2000 Feb; 52(2):235-40. PubMed ID: 10671952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRH in Cushing's syndrome.
    Müller OA; Stalla GK; von Werder K
    Horm Metab Res Suppl; 1987; 16():51-8. PubMed ID: 2832289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma corticotropin and cortisol responses to ovine corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), CRH plus AVP, and CRH plus metyrapone in patients with Cushing's disease.
    Dickstein G; DeBold CR; Gaitan D; DeCherney GS; Jackson RV; Sheldon WR; Nicholson WE; Orth DN
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2934-41. PubMed ID: 8768855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of metyrapone pretreatment on adrenocorticotropin secretion induced by corticotropin-releasing hormone in normal subjects and patients with Cushing's disease.
    Totani Y; Niinomi M; Takatsuki K; Oiso Y; Tomita A
    J Clin Endocrinol Metab; 1990 Mar; 70(3):798-803. PubMed ID: 2155255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.
    Oliveira JH; Vieira JG; Abucham J; Lengyel AM
    J Endocrinol Invest; 2003 Mar; 26(3):230-5. PubMed ID: 12809173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of serum macrophage migration inhibitory factor levels to stimulation or suppression of the hypothalamo-pituitary-adrenal axis in normal subjects and patients with Cushing's disease.
    Isidori AM; Kaltsas GA; Korbonits M; Pyle M; Gueorguiev M; Meinhardt A; Metz C; Petrovsky N; Popovic V; Bucala R; Grossman AB
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1834-40. PubMed ID: 11932327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.